Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative sivelestat sodium for lung protection in thoracoscopic heart surgery
ChiCTR2400084593Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sivelestat in Cardiac valve disease (VHD) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: oxygenation index, alveola-arterial partial oxygen pressure difference (A-aDo2) and 2 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR2400084593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084593.